Results 211 to 220 of about 25,158 (238)
Some of the next articles are maybe not open access.

Assay of CB1 Receptor Binding

2022
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be ...
Gasperi V, Savini I, Catani MV
openaire   +3 more sources

The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)

Behavioural Pharmacology, 2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory animals, cannabinoid CB1 receptor antagonism decreases motivation for palatable foods, and most recently, the CB1 receptor antagonist SR141716A, or rimonabant (Acomplia), was reported to produce weight loss in obese human ...
S J, Ward, L A, Dykstra
openaire   +2 more sources

CB1 Cannabinoid Receptor Ligands

Mini-Reviews in Medicinal Chemistry, 2005
The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications.
Ganesh A, Thakur   +2 more
openaire   +2 more sources

Assay of CB1 Receptor Binding

2016
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful ...
Catani, VM, GASPERI, VALERIA
openaire   +4 more sources

Aminopyrazine CB1 receptor inverse agonists

Bioorganic & Medicinal Chemistry Letters, 2008
A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential.
David J, Wustrow   +14 more
openaire   +2 more sources

Diaryl piperidines as CB1 receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2010
The syntheses and SAR investigations of novel CB(1) receptor antagonists based on a 1,2-diaryl piperidine core have been described. Optimization of this core afforded a compound with robust in vivo potency by reducing food intake in a mouse DIO model.
Jack D, Scott   +13 more
openaire   +2 more sources

Allosteric Modulation of the Cannabinoid CB1 Receptor

Molecular Pharmacology, 2005
We investigated the pharmacology of three novel compounds, Org 27569 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide), Org 27759 (3-ethyl-5-fluoro-1H-indole-2-carboxylic acid [2-94-dimethylamino-phenyl)-ethyl]-amide), and Org 29647 (5-chloro-3-ethyl-1H-indole-2-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide, 2 ...
Martin R, Price   +16 more
openaire   +2 more sources

Peripherally restricted CB1 receptor blockers

Bioorganic & Medicinal Chemistry Letters, 2013
Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease. These agents, representing diverse chemical series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor ...
openaire   +2 more sources

The role of the CB1 receptor in the regulation of sleep

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
During the 1990s, transmembranal proteins in the central nervous system (CNS) that recognize the principal compound of marijuana, the delta-9-tetrahydrocannabinol (Delta9-THC) were described. The receptors were classified as central or peripheral, CB1 and CB2, respectively. To this date, it has been documented the presence in the CNS of specific lipids
openaire   +2 more sources

Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!

Journal of Neuroscience Methods, 2008
The study of endogenous cannabinoid CB1 receptor proteins in neuronal tissues and cells relies on the availability of highly specific antibodies. We have tested the ability of a series of CB1 antibodies to detect endogenous receptors in brain as well as hemagglutinin (HA)-tagged receptors transfected into HEK-293 cells using a combination of ...
Natasha L, Grimsey   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy